Search results

Found 34 releases mentioning: pradaxa

Business Wire Australia and New Zealand

Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations

11 Jul 2017

Business Wire Australia and New Zealand

New data reveal high rates of stroke history in asymptomatic atrial fibrillation patients

21 Jun 2017

Business Wire Australia and New Zealand

Uninterrupted Pradaxa® Showed Less Major Bleeding than Warfarin in Atrial Fibrillation Patients Undergoing Catheter Ablation

21 Mar 2017

Business Wire Australia and New Zealand

New Data Show High Adherence Rates with Pradaxa® (dabigatran etexilate) in NVAF Patients

06 Dec 2016

Business Wire Australia and New Zealand

Patient enrolment completed for RE-DUAL PCI™ study assessing dabigatran in atrial fibrillation patients after PCI with stenting

12 Nov 2016

Business Wire Australia and New Zealand

Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind® usage in clinical practice

16 Aug 2016

Business Wire Australia and New Zealand

Pradaxa®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain

12 May 2016

Business Wire Australia and New Zealand

Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations

04 Apr 2016

Business Wire Australia and New Zealand

Boehringer Ingelheim launches RE-COVERY DVT/PE™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate)

24 Mar 2016

Business Wire Australia and New Zealand

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

27 Nov 2015

Business Wire Australia and New Zealand

Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® in Routine Clinical Care

11 Nov 2015

Business Wire Australia and New Zealand

Boehringer Ingelheim Presents New idarucizumab (Praxbind®) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran

10 Nov 2015

Display

Sort by

Your saved searches

If you regularly search for a topic or keyword, you can save the current search criteria for quick access in future. Saved searches will be listed here.

Refine results